Form 4: X4 Pharmaceuticals Director Murray Stewart Receives Annual Equity Grant

X4 Pharmaceuticals, Inc. Director Murray Stewart was granted 1,500 restricted stock units (RSUs) as part of his annual compensation for board service, aligning his interests with shareholders.

Summary

• Murray Stewart, a Director of X4 Pharmaceuticals, Inc. (XFOR), acquired 1,500 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 9, 2025.
• The RSUs were granted as an annual award for his service on the Board of Directors.
• These RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, contingent on continued board service.
• Full vesting will also occur upon a change in control of X4 Pharmaceuticals, Inc.
• Following this transaction, Murray Stewart directly beneficially owns 7,883 shares of Common Stock.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the RSU grant aligns the director's interests with shareholders, which is generally viewed favorably. However, it's a routine compensation event and not indicative of significant operational or financial news.

Positives

• The grant of Restricted Stock Units (RSUs) to Director Murray Stewart aligns his financial interests with those of the company's shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice that helps attract and retain experienced board members.

Future Outlook

The granted RSUs are subject to future vesting, which will occur on the earlier of the one-year anniversary of the grant date or the company's next annual meeting of stockholders, provided the director continues board service. Full vesting will also be triggered by a change in control of the Issuer.

Industry Context

The granting of Restricted Stock Units (RSUs) to non-employee directors is a common and widely accepted practice across various industries, including the biotechnology and pharmaceutical sectors, to compensate board members and align their interests with long-term company performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of director compensation is a standard practice in the biotechnology and pharmaceutical industries, comparable to compensation structures at companies like Moderna, BioNTech, or Regeneron Pharmaceuticals, which often include equity components to incentivize long-term value creation.
• The vesting schedule, tied to continued service and accelerated by a change in control, is also a typical feature of such equity grants, reflecting common corporate governance practices.

Stakeholder Impact

• Shareholders: The RSU grant aligns the interests of Director Murray Stewart with those of the shareholders, as the value of his compensation is tied to the company's stock performance, potentially encouraging decisions that enhance shareholder value.

Next Steps

• The RSUs granted to Director Murray Stewart will vest based on the specified conditions: either the one-year anniversary of the grant date or the Issuer's next annual meeting of stockholders, subject to continued board service.
• The RSUs will also vest in full upon the occurrence of a change in control of the Issuer.

Key Dates

Keywords

X4 Pharmaceuticals, XFOR, Form 4, SEC filing, Insider transaction, Restricted Stock Units, RSU, Director compensation, Equity grant, Corporate governance